Cleveland clinicians are helping rewrite the prostate cancer playbook. Doctors at University Hospitals Seidman Cancer Center led a randomized trial that shows which men with recurrent prostate cancer are most likely to benefit from adding hormone therapy to salvage radiation after prostatectomy. The research found that patients whose tumors fall into a genomic subtype called luminal B had substantially lower rates of recurrence and metastasis when apalutamide was added, while non‑luminal B patients saw no clear benefit. Investigators say these results represent the first prospectively validated predictive biomarker in prostate cancer and carry immediate implications for how clinicians tailor post‑surgery care.
How the trial was set up
The phase II BALANCE study (NRG GU006) enrolled 295 men with rising PSA after prostatectomy and randomized them to receive salvage radiotherapy plus either apalutamide or placebo, with patients stratified by a PAM50 genomic subtype. According to ASTRO, tumors were categorized as luminal B (n=127) or non‑luminal B (n=168), and patients were followed for a median of five years. The study was presented as a late‑breaking abstract at ASTRO’s annual meeting, where investigators emphasized that the trial was both biomarker‑driven and double‑blinded.
What the numbers mean
Reporting from The ASCO Post notes that among luminal B patients, five‑year biochemical progression‑free survival was about 72% with apalutamide compared with 54% with placebo. Five‑year metastasis‑free survival in this group improved from roughly 82% to 95%. In contrast, outcomes for non‑luminal B patients were essentially unchanged when hormone therapy was added. Investigators reported hazard ratios and p‑values that they say validate PAM50 as a predictive test for benefit from androgen‑receptor blockade in this setting.
What clinicians are saying
“We now have a tool that lets us tailor treatment based on a tumor’s biology,” said Dr. Daniel Spratt, the trial’s principal investigator, in a University Hospitals news release that described the findings as practice‑changing. The UH release explains that PAM50 was originally adapted from a breast‑cancer classifier and was implemented here as a Decipher‑enabled biomarker to distinguish luminal B tumors from other subtypes. Investigators also underscored that hormone therapy carries well‑known side effects, which is why a predictive biomarker that can steer some men away from unnecessary treatment could be especially valuable.
Trade‑offs and next steps
Investigators and meeting reporters noted that apalutamide increased some higher‑grade adverse events, and that the strength and clarity of benefit in luminal B patients make a large phase III confirmatory trial unlikely, according to The ASCO Post. Because the study identifies both the patients who benefit and those who do not, authors argue that the data could reshape shared‑decision conversations and influence guideline thinking about when to add hormone therapy after prostatectomy. Experts quoted in conference coverage urged rapid incorporation of these results into post‑surgery decision tools, while keeping a close eye on longer‑term follow up for any emerging safety signals.
Local angle: Cleveland’s role
The BALANCE trial puts a spotlight on Cleveland’s role in prostate‑cancer research, with UH Seidman investigators leading a multi‑center effort that links genomic profiling to a concrete treatment choice. Local station WKYC aired a March 18 segment on what the findings could mean for men in Northeast Ohio who are weighing salvage therapy. For patients, the immediate takeaway is that genomic subtyping may soon become a routine part of post‑surgery treatment planning at major cancer centers.
Patients and families are encouraged to discuss PAM50 testing, the potential benefits of adding hormone therapy, and the side‑effect trade‑offs with their oncology team. For more detail on the presentation and the data, see the original release from ASTRO and the University Hospitals news release summarizing the BALANCE (NRG GU006) results.
